End-to-End Evidence Management Can Enable Value-Based, Personalized Healthcare.

• Thank you for joining us for this FierceLive! Webinar. We will begin momentarily.

• The audio will be streamed live over the Internet, so please make sure your computer speakers or headphones are turned on and your volume is turned up.

• To download the slide deck, please click the Download Slides widget at the bottom of your screen.

• During the presentations, you can submit your questions in the “Q&A” widget to the right of this screen. The speakers will answer questions at the end of the webinar.

Enjoy the presentation!

Presented by: Deloitte.
End-to-End Evidence Management Can Enable Value-Based, Personalized Health Care

March 31, 2016
Speakers

Terry Hisey
Principal, Deloitte LLP
Life Science and Health Care
rhisey@deloitte.com

Mary Cummins
Principal, Deloitte LLP
Life Science and Health Care
mcummins@deloitte.com

This publication contains general information only and Deloitte is not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor. Deloitte shall not be responsible for any loss sustained by any person who relies on this publication.


Certain services may not be available to attest clients under the rules and regulations of public accounting.

Copyright © 2015 Deloitte Development LLC. All rights reserved.
Discussion Areas

• How’s the overall health care sector changing and what kind of new reality does this create for Life Sciences?

• What is needed in a fact based shift to value future?

• Biopharma’s industry response with evidence.

• How are different stakeholders thinking and acting around evidence?

• What are key questions stakeholders need to answer and act on?
We are in an unprecedented period of change in the health care ecosystem

Increased scrutiny on “value” in the US as those financing health care seek new alternatives to deal with unsustainable cost burden and relatively poor ROI on per capita health spend; continuing pressure globally

**New Health System Payment Models**

A *wide range of payment models* is now in use between payers and providers, changing their fundamental businesses and behaviors

- Providers funded via Traditional Fee for Service through Shared Savings, Shared Risk and through to Global Capitation; growing traction for Bundled Payments

**Stakeholders Changing**

Life Sciences companies must now engage a *new set of decision makers and stakeholders*

- Consolidating providers and payers, providers with their own plans, physicians employed by hospital systems, new influencers …

**Increasing Evidence Demands**

Growing demand for *new forms of evidence* from variety of stakeholders (Government, payers, providers, etc.)

**Intensifying Public Scrutiny**

… And the value debate is being amplified as biopharma companies come under scrutiny for *pricing and affordability*

Payers and providers are under intense pressure to redefine their businesses in search of sustainable profitability and growth – the default discussion with Life Sciences manufacturers becomes cost as a proxy for value
Health care providers are living in a “New Normal” with a focus on value rather than volume.

The evolution of the U.S. health system from volume- to value-based care (VBC) is under way, spurred by widespread efforts to control/reduce costs, improve outcomes, and obtain more value for money spent.

Organizations are increasingly focused on population health and how they can drive improved outcomes through value based care delivery models.
This “New Normal” has significant implications for life science companies.

In order to prove value and articulate their value proposition, companies will need a strong evidence lifecycle management capability.
The imperative to leverage evidence throughout the product life cycle is driving change to business processes

- Real World Evidence (RWE) has emerged as a powerful and broad based capability to shape and inform the shift to value based, personalized health care.

- What began as comparative research and outcomes research has matured into an ever expanding framework of data and analytic capabilities to enable more accurate and more efficient health care and health product decision making.

### Changing RWE models within the LS industry

<table>
<thead>
<tr>
<th>RWE Mandate</th>
<th>IT &amp; Informatics</th>
<th>Source of Data and Tools</th>
<th>Value Creation</th>
</tr>
</thead>
<tbody>
<tr>
<td>From observing and understanding…</td>
<td>From tightly coupled data and analytics solutions for technical “experts”…</td>
<td>From data providers seen as vendors and suppliers…</td>
<td>From evidence generation primarily supports commercial objectives…</td>
</tr>
<tr>
<td>…to shaping and Influencing</td>
<td>…to standards based, modular architectures that empower domain experts</td>
<td>…to data providers seen as partners and collaborators</td>
<td>…to evidence informing product design and patient care</td>
</tr>
</tbody>
</table>

The move to new evidence strategies and capabilities has implications for technology investments, organizational constructs, and new business models.
The effective use of real world data and evidence can help revolutionize the life sciences industry…

...But in order to advance the use of data and evidence, organizations must overcome many challenges

---

### Operational Complexities

#### Exponential growth in volume of data:
- Crushing infrastructure
- Outdated solutions
- Processing bottlenecks
- Cost pressures
- Burden to manage
- Complex to secure

#### New types of data compounding challenges:
- Social, mobile
- Real world data (claims, EMR, survey)
- Clinical trials
- Genomics
- Post marketing safety surveillance

#### Dependency on historical reporting & manual heroics:
- Slow, inefficient
- Insufficient granularity
- Siloed solutions
- Incomplete views
- Lack business drivers
- Talent pressures

#### Decisions & actions constrained by insights available:
- Missing, too late
- Hands of few
- Back end of the process
- Slow to implement
- Opportunity costs
- Competitive threats

---

### Strategic Considerations

- Operating costs
- Risk reduction
- Data & Information Assets
- Competitive threats
- Changing industry boundaries
- Regulatory demands & compliance
- Global
- Talent
Evidence Life Cycle Management (ELM) and why is it important?

Throughout life sciences organizations, data and evidence are generated and used for various purposes. Historically, this information is underutilized due to organizational structure, culture and lack of technology. Because of this, opportunities are missed to realize the full value this information brings to an organization and the many decisions that are made on a daily basis.

What is Evidence life cycle management?
An end-to-end approach to leveraging the data, evidence, and knowledge assets of a life sciences organization that breaks down traditional siloes that exist and enable insight driven decision making from R&D through commercialization.

End to End Evidence Management is an enterprise wide strategy with implications across the organization.

As health care shifts to a value-based model
ELM will play a vital role in the success of life sciences companies
An ‘End-to-End Evidence Management’ approach enables the integration of evidence driven insights and knowledge across the organization.

**Optimizing Value**
Applying RWE to develop, support and sustain a compelling value story for approved therapeutic interventions—and to inform new opportunities for therapeutic discovery and development via effective end-to-end RWE management.

**Generating Value**
Maximizing potential for clinical and commercial success, leveraging RWE to segment patient populations for optimal therapeutic response and safety, and to assess category dynamics to support pricing and market access strategies.

**Discovering Value**
Enhancing pre-clinical and clinical research productivity through precise target and patient cohort identification.

**Evidence Management**

- **Research**
- **Clinical Development**
- **Commercialization**
Evidence has multiple complex dimensions that must be considered in an end-to-end evidence strategy

**Domain Complexity**
Various functions are solving for different questions and have different data needs

**Geographic**
Discrepancies and differing needs in breadth and depth of data coverage

**Disease Nuance**
Treatment dynamics and patient profiles unique to each disease state

**Operational**
Execution, integration, resources, and outreach challenges
There is a fundamental need for new kinds of data and evidence, but also an understanding that these will be used differently by various groups.

An evidence strategy is no longer being considered optional, rather integral to the success of any therapeutic pipeline. But the strategy and governance around managing these sources across functions is becoming challenging.
In order to compete in the evolving health care landscape, life science organizations must become increasingly “insight driven”

An Insight-Driven Organization (IDO)

is one which embeds analysis, evidence, and reasoning into the decision-making process. An IDO sees analytics as a core capability embedded across the organization – from strategic planners through line workers – providing insight at the point of action and supporting decision-making at the right place and the right time.

When humans rely on their own experiences and knowledge, augmented by a stream of analytics-driven insights, the impact on value can be exponential

Evidence-based insights feed human decision making

Impact

• Improve the speed of decision-making
• Make better decisions
• Decrease the cost of decision-making
• Become more innovative
E2E evidence management is a strategic business capability that can help enable innovation, efficiency, and commercial benefits of a business. It is best conceived by asking and answering a set of “interdependent questions” to arrive at the right decisions and commitments:

- Do we have a common definition and accepted metrics for “evidence” or are they part of the challenge to developing a strategy?
- Are we configured in a way to deliver optimal evidence capabilities?
- What is the appropriate funding allocation for an evidence strategy?
- What impacts will this strategy have on internal operations, governance/regulatory, compliance, commercialization, data systems, vendor and customer relationships?
- What components (capabilities, technologies, etc.) are essential to successfully implement and sustain this strategy?
- What are the implications of moving forward or not moving forward with an E2E evidence management strategy?
- How do we leverage evidence across all product development, marketing, and distribution channels?
- Do people and organizations have the level of “Evidence Intelligence” to drive value?
- What investments or collaboration do we need to invest in to build capability?
- How do various functions rely on evidence to drive insight decision-making?
A few essential elements are necessary across all organizations for an effective E2E evidence strategy

1. Clear, top-down sponsorship and enterprise-wide alignment

2. Broad understanding of the necessary changes to the organization’s business and operating model

3. A plan for external collaborations to support the new business and operating model

4. Next-generation IT and informatics infrastructure and human capital to support the new model
Thank You
Thank you for joining us!

• Thank you for joining us for this FierceLive! Webinar!

• This webinar has been recorded and will be available on-demand within 24 hours. You will receive a notice when the recording is available.